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A Selective Novel Peroxisome Proliferator–Activated
Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits
Proliferation of CLL Cells In Vitro and In Vivo
Davorka Messmer,1 Kymmy Lorrain,1 Karin Stebbins,1 Yalda Bravo,1 Nicholas Stock,1 Geraldine Cabrera,1
Lucia Correa,1 Austin Chen,1 Jason Jacintho,1 Nicholas Chiorazzi,2 Xiao Jie Yan,2 David Spaner,3,4,5
Peppi Prasit,1 and Daniel Lorrain1
1

Inception Sciences, San Diego, California, United States of America; 2The Feinstein Institute for Medical Research, North Shore–LIJ
Health System, Manhasset, New York, United States of America; 3Division of Molecular and Cellular Biology, Sunnybrook Research
Institute, Toronto, Ontario, Canada; and Departments of 4Medical Biophysics and 5Immunology, University of Toronto, Toronto,
Ontario, Canada

Tumor-specific metabolic changes can reveal new therapeutic targets. Our findings implicate a supporting role for fatty acid
metabolism in chronic lymphocytic leukemia (CLL) cell survival. Peroxisome proliferator–activated receptor (PPAR)-α, a major transcriptional regulator of fatty acid oxidation, was recently shown to be upregulated in CLL. To evaluate PPARα as a potential therapeutic target, we developed a highly selective, potent small molecule antagonist of PPARα, NXT629. NXT629 inhibited agonistinduced transcription of PPARα-regulated genes, demonstrating target engagement in CLL cells. Furthermore, NXT629 induced
apoptosis of CLL cells even in the presence of a protective microenvironment. To mimic the proliferative lymphoid compartment
of CLL, we examined the activity of NXT629 on CLL cells that were stimulated to proliferate in vitro. NXT629 reduced the number
of leukemia cells undergoing cell division. In addition, in two xenograft mouse models of CLL (one a model for nondividing and
one for dividing CLL), NXT629 reduced the number of viable CLL cells in vivo. Overall, these results suggest that fatty acid metabolism promotes survival and proliferation of primary CLL cells and that inhibiting PPARα gene regulation could be a new therapeutic approach to treating CLL.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2015.00139

INTRODUCTION
Chronic lymphocytic leukemia (CLL)
is the most common adult leukemia in
the Western world, leading to ~5,000
deaths annually (1). CLL is characterized
by an accumulation of monoclonal mature B cells in blood, secondary lymphoid tissues and bone marrow. Despite
major advances in the field, there is no
curative therapy for CLL to date (2).
Current treatment approaches aim at
achieving minimal residual disease,

which is associated with superior longterm outcome (3). Treatment avenues,
such as those targeting pathways downstream of the B cell receptor, such as
Syk, Btk and PI3Kδ (4–9), that are currently being evaluated in clinical trials
or have recently been approved by the
U.S. Food and Drug Administration
(such as ibrutinib) are focused on kinases. Surprisingly, little attention has
been given to targeting metabolic enzymes in CLL. While the traditional
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view has been that cancer cells are fueled by glucose, named the “Warburg effect” after Otto Warburg (10,11), recent
studies demonstrate the involvement of
fatty acid oxidation (FAO) in cancer cell
viability. Some solid tumors including
prostate, ovarian and renal cell carcinoma rely on fatty acids to satisfy their
metabolic needs (12–16). Solid tumors
that are initially dependent on glucose
can undergo a metabolic switch upon
detachment from the extracellular matrix and start depending on FAO for survival (12). In addition, hypoxia and
oncogenic RAS increase fatty acid uptake by tumor cells (17). Inhibition of
FAO with Etomoxir, an irreversible small
molecule inhibitor of CPT1A, the ratelimiting enzyme for fatty acid import
into mitochondria (18), sensitized AML
cells to apoptosis induction by ABT-737,
an inhibitor of Bcl-2 and Bcl-xL (19). Fur-
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thermore, some evidence points toward
a critical role for FAO in the viability of
leukemia-initiating cells. For instance,
the CPT1A inhibitor Etomoxir decreases
the number of leukemia-initiating cells
in primary human AML samples (19),
and FAO signaling downstream of PML
was found to be critical for maintenance
and function of hematopoietic stem cells
and possibly leukemia-initiating cells
(20).
Peroxisome proliferator–activated receptors (PPARs) are a family of ligand
activated nuclear hormone receptors
comprised of three isoforms: PPARα,
PPARδ and PPARγ. PPARα, also known
as NR1C1 (nuclear receptor subfamily1,
group C, member 1) is a major transcriptional regulator of lipid metabolism. Endogenous PPARα ligands include free fatty acids and eicosanoids as
well as oleoylethanolamide (OEA), a
naturally occurring lipid (21). Upon
ligand binding, PPARα induces transcription of a number of genes, resulting in a shift toward β-oxidation (for
example, CPT1A) and away from glucose oxidation (for example, PDK4)
(22).
It was recently shown that compared
with normal B cells, CLL cells overexpress PPARα, rendering them dependent on β-oxidation for energy (23).
This metabolic strategy helps account
for some of the pathogenic characteristics of CLL, including immunosuppression and drug resistance. These reports
establish PPARα as a promising molecular target for the treatment of this cancer. However, to date, no clinically relevant, selective PPARα antagonists have
been available to address this idea in
human trials. We have recently described the discovery and synthesis of a
family of novel, selective and bioavailable PPARα antagonists that can bind
reversibly to the ligand binding site and
effectively compete with both synthetic
and endogenous PPARα agonists (24).
Herein, we evaluated the activity of the
PPARα antagonist NXT629 on CLL viability and proliferation in vitro as well
as tumor burden in vivo.

MATERIALS AND METHODS
Patient Samples, Isolation of CLL
B cells, Cell Culture and Reagents
Blood samples were collected from patients at The Feinstein Institute for Medical Research, North Shore–LIJ Health
System (Manhasset, NY, USA), and the
Sunnybrook Odette Cancer Center
(Toronto, Canada) who satisfied diagnostic and immunophenotypic criteria for
common B-cell CLL after providing written informed consent in compliance with
the Declaration of Helsinki (25) and the
Institutional Review Board of the North
Shore–LIJ Health System and the Sunnybrook Health Sciences Center. Blood was
collected from patients for whom clinical
information and laboratory data were
available. For a set of patients (from
N Chiorazzi), immunoglobulin heavychain variable region gene (IGHV) and
immunoglobulin light-chain variable region gene (IGLV) DNA sequences were
also available. For some experiments, the
CLL cells were purified from frozen peripheral blood mononuclear cells
(PBMCs) via negative selection by using
anti-CD2 and anti-CD14 magnetic beads
(Miltenyi Biotech).

tion), which was used as vehicle control
in all experiments. Determination of CLL
cell viability was based on the analysis of
mitochondrial transmembrane potential
(Δψm) using 3,3′-dihexyloxacarbocyanine
iodide (DiOC6) (Invitrogen), and cell
membrane permeability to propidium
iodide (PI) (Sigma-Aldrich). For viability assays, 100 μL of the cell culture was
collected at the indicated days and
mixed with media containing 100 μL of
40 μmol/L DiOC6 and 10 μg/mL PI. The
cells were then incubated at 37°C for
15 min and analyzed within 30 min by
flow cytometry by using the flow cytometer Accuri C6 (Accuri). Data were
analyzed by using the CFlowPlus software (Accuri). The percentage of viable
cells was determined by gating on PI
negative and DiOC6 bright cells.

Isolation of B Cells from Healthy
Volunteers
Peripheral blood mononuclear cells
were isolated from the blood of normal
volunteers over a Ficoll-Hypaque density
gradient. Anonymous blood samples
were purchased from the San Diego
Blood Bank; therefore, no Institutional
Review Board approvals were necessary.
B cells were isolated by positive selection
using CD19+ beads (Milenyi Biotech) per
the manufacturer’s instructions. Cells
were cultured and viability was monitored as described below.

Cocultures
Macrophages (J774A.1) were obtained
from ATCC (ATCC® TIB67™ and
CRL-11882™) and plated in 96-well
plates at a density of 50,000 cells per
well. OP9 cells were also obtained from
ATCC (ATCC® CRL-2749™) and plated
at 10,000 cells/well. Macrophages and
OP9 cells (26) were exposed to 10 μg
mitomycin C (Sigma-Aldrich M4287) for
3 h to prevent proliferation. The cells
were then washed three times with
media to remove the mitomycin C.
Cells were plated in RPMI/10% FCS,
and CLL cells were subsequently plated
over the layer of mitomycin C–treated
macrophages or OP9 cells. NXT629 or
vehicle control was added to the cells at
the beginning of the coculture and incubated in a 37°C/5% CO2 incubator for
7 d. After 7 d, the CLL cells were collected and stained with DiOC6/PI and
analyzed for viability as described
above.

Measurement of Cell Viability
CLL cells were cultured at 2 × 105
cells/mL in 100 μL media in 96-well
plates (Costar, Corning Inc.) in RPMI
1640/10% fetal calf serum (FCS). All inhibitors were prepared in dimethyl sulfoxide (DMSO) (0.1% final concentra-

CLL Proliferation Assay
PBMCs were isolated from the blood
of normal volunteers (purchased anonymously from the San Diego Blood Bank)
over a Ficoll-Paque PLUS density gradient (GE Healthcare). CD2+ T cells were
isolated from PBMCs by positive selec-
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tion using anti-CD2 beads (Miltenyi
Biotech) following the manufacturer’s instructions. To activate T cells, they were
cultured on a 24-well plate (Costar/
Corning Inc.) at 1 × 106 cells/mL in 1 mL
of culture media (RPMI 1640 supplemented with 10 mmol/L HEPES
[GIBCO-BRL], penicillin [100 U/mL]–
streptomycin [100 μg/mL] (Gibco/
Invitrogen) and 10% FCS [ATCC]) in the
presence of 20 μL CD3/CD38 Dynabeads
(Invitrogen) per 106 T cells for 3 d. T cells
were collected, resuspended at 2 × 107
cells/mL in fresh medium containing
12 μg/mL mitomycin C and incubated
for 3 h at 37°C. At this point, the T cells
were washed four times with fresh
media and frozen by using Recovery Cell
Culture freezing media (Gibco/Life
Technologies) in liquid N2 until use. CLL
proliferation induced by frozen versus
fresh T cells was comparable (data not
shown). Thus, frozen T cells were used
for all experiments.
To set up the CLL proliferation assay,
CLL PBMCs were thawed from frozen
vials and cultured at 1.4 × 105 CLL cells/
well in 100 μL of the above-listed culture
media for 2 h in the presence of PPARα
antagonist or vehicle control. Mitomycin
C–treated, activated T cells were added
at 6 × 104 T cells/well in 100 μL of the
above-listed culture media supplemented with hrIL-4 (5 ng/mL, R&D Systems) and hrIL-10 (15 ng/mL, R&D Systems). Cells were cultured for 5–8 d. In
some experiments, CLL cells were prelabeled with carboxyfluoresceinsuccinimidyl ester (CFSE) (Invitrogen) after the
manufacturer’s instructions before coculture. Five days after coculture, CLL cells
were stained with CD19-APC (Becton
Dickinson), and proliferation was assessed by flow cytometry (Accuri cytometer) gating on CD19+ CFSE+ cells. In
the majority of the experiments, if not
otherwise indicated, the number of viable CLL cells was analyzed by staining
with DiOC6/PI as described above and
collecting each sample for 30 s via flow
cytometry. The number of viable cells
was determined by gating on DiOC6
bright and PI negative cells.

Cell Cycle Analysis
CLL cells were cultures as above to
trigger proliferation. At d 8, cells were
collected and analyzed for cell cycle progression by using the FxCycle PI/RNase
staining solution (Molecular Probes, Life
Technologies) according to the manufacturer’s instructions.
Isolation of RNA and cDNA Synthesis
Purified CLL cells were plated at 6.8 ×
106 cells/mL in 1 mL media in a 12-well
plate. Cells were exposed to antagonist
NXT629 for 2 h, followed by an agonist
for 48 h, as described in the respective
figure legends. RNA was isolated from
CLL cells by using the RNeasy kit (Qiagen). A total of 100 ng RNA was used in
each cDNA reaction by using the IScript
reaction mix (Bio-Rad) following the
manufacturer’s instructions.
Real-Time Reverse Transcriptase
Polymerase Chain Reaction
Reverse transcription reactions were
performed by using the iTaqUniversal
SYBR® Green supermix (Bio-Rad) following the manufacturer’s instructions.
Each reaction contained 2.5 ng reversetranscribed RNA (based on the initial
RNA concentration) in 20 μL final reaction volume. The reaction conditions
were as follows: 95°C for 30 s, 45 cycles
of 95°C for 4 min followed by 59°C for
5 min, 65°C for 5 min and finally 95°C
for 5 min. Primer sequences used were as
follows: β-actin-F: GCT GTG CTA CGT
CGC CCT G, β-actin-R: GGA GGA GCT
GGA AGC AGC C, PDK4-F: GGAGC
ATTTCTCGCGCTACA, and PDK4-R:
ACAGGCAATTCTTGTCGCAAA.
Primers were synthesized by Integrated
DNA Technologies. The polymerase
chain reaction (PCR) was carried out by
using the C1000Touch Thermal Cycler
(Bio-Rad).
CLL Mouse Model
Two different CLL mouse models were
evaluated. NOD/Shi-scid,γcnull (NSG)
mice, a NOD/SCID-derived strain, that
lacks the IL-2 receptor family common
cytokine receptor γ chain gene (γc), ren-
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dering animals completely deficient in
lymphocytes, including natural killer
cells, were used for this study. Female
NSG mice (12–14 wks at study initiation)
were purchased from The Jackson Laboratory. Animals were given food and
water ad libitum and allowed to acclimate
for at least 1 wk before initiation of experiments. All protocols were approved
by the Inception Sciences Institutional
Animal Care and Use Committee.
Model for resting CLL. CLL PBMCs
from two patients were pooled, and
CFSE was labeled and randomized
among the groups. The 108 CFSE-labeled
cells were delivered by an intravenous
bolus injection (50 μL) into the tail vein
of NSG mice. Immediately after injection
of CLL cells, groups of five mice received daily dosing of vehicle control
(saline, 10 mL/kg, intraperitoneal),
NXT629 at 30 mg/kg or fludarabine at
50 mg/kg. Mice were sacrificed 4 wks
after engraftment, and the splenocytes
were stained with hCD19 and hCD5 and
analyzed by flow cytometry.
Model for proliferative CLL. The Institutional Review Board and the Institutional Animal Care and Utilization Committee of the North Shore–LIJ Health
System sanctioned these studies. T cells
were purified from CLL PBMCs using
Milteny anti-CD3 beads, resuspended in
1 × 106 cells/mL and stimulated with
anti-CD3/CD28 Dynabeads (30 μL/mL)
in the presence of IL-2 (36 U/mL) in
RPMI 1640/10% FCS for 3 d. Next, beads
were removed from the cultures, and the
cells were cultured in media supplemented with IL-2 for an additional 4 d.
Preactivated human T cells (5 × 105) were
administered in 4- to 8-wk-old NSG mice
(The Jackson Laboratory) by injection
into the retro-orbital plexus (50 μL). After
confirming the presence of human T cells
in the blood of recipient mice (10 d after
injection), CLL PBMCs from the same patient (2 × 107) were delivered by an intravenous (50 μL) injection into the retroorbital plexus. At the time of CLL cell
injection, mice received vehicle control or
NXT629, 30 mg/kg of mouse weight,
which was given by intraperitoneal injec-
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Table 1. IC50 values (inhibition in antagonist mode) for human PPARα, PPARδ and PPARγ.
Human PPAR

NXT629

PPARα
PPARδ
PPARγ

NXT962

78 nmol/L
>30,000 nmol/L
>30,000 nmol/L

>15,000 nmol/L
>30,000 nmol/L
>30,000 nmol/L

Table 2. IC50 values μmol/L using NXT629 (inhibition in antagonist mode) for human nuclear
hormone receptors?
PPARα
0.077 ± 35

PPARδ

PPARγ

ERβ

GR

TRβ

6.0 ± 3.2

15 ± 19

12 ± 8

26 ± 21

57 ± 27

tions daily for 2 wks. All mice were
killed at the end of experiment, and the
spleen and bone marrow (BM) were collected for flow cytometric analyses.
Spleen and BM cells were stained by
using anti-mCD45, anti-hCD45, antihCD5, anti-hCD19, anti-hCD4 and antihCD8 antibodies.
Statistical Analysis
Statistical significance was determined
by using the Student t test. The p values
<0.05 were considered significant. Median inhibitory concentration (IC50) values were determined using nonlinear regression (curve fit) analysis with Prism
software (GraphPad Software).
All supplementary materials are available
online at www.molmed.org.
RESULTS
NXT629 Inhibits Transcription of PPARα
Target Genes
We recently designed several novel
small-molecule PPARα selective antagonists. One such molecule, NXT629, was
used in the current set of experiments to
determine the role of this nuclear hormone receptor in CLL B-cell function.
NXT629 has an IC50 value of 78 nmol/L

against PPARα in a luciferase reporter
assay (Invitrogen) (Table 1) and is selective against other nuclear hormone receptors (Table 2) (24). In addition, the
negative control compound NXT962
was synthesized. NXT962 has a similar
chemical structure, but does not significantly inhibit PPARα in the luciferase reporter assay (IC50 = 15 μmol/L). A recent
study demonstrated that CLL cells show
increased expression levels of PPARα
relative to B cells from healthy donors
(23). As a transcriptional regulator,
PPARα controls the expression of a
number of genes, including those involved in β-oxidation (27,28). Target engagement of NXT629 in CLL cells was
determined by measuring inhibition of
PPARα agonist–induced expression of
the PPARα target gene pyruvate dehydrogenase kinase isoform 4 (PDK4) by
real-time quantitative PCR (QPCR). The
synthetic agonist GW590763 (29) caused
a three-fold increase in PDK4 mRNA expression, which was dose-dependently
inhibited by NXT629 (Figure 1A), but
not by the negative control compound
NXT962 (Figure 1B). The natural agonist
OEA caused a six-fold upregulation of
PDK4 in CLL cells, which was almost
completely inhibited by 3 μmol/L
NXT629 (Figure 1C). NXT629 also inhib-

ited mRNA upregulation of the target
gene carnitine/acylcarnitine translocase
(CACT/SLC25A20), a rate-limiting protein for β-oxidation (Figure 1D).
PPARα Antagonist Is Cytotoxic to CLL
Cells Even in the Presence of a
Protective Microenvironment
PPARα was previously shown to mediate protection of CLL cells from harsh microenvironmental conditions, including
the presence of cytotoxic agents (23,30).
This result suggests that PPARα plays a
role in CLL cell viability. To test this, we
examined to what extent PPARα inhibition, by using a selective small molecule
antagonist, is cytotoxic to CLL cells in
vitro. NXT629 dose-dependently induced
apoptosis of resting CLL cells (Figure 2A).
The concentration at which 50% of the
cells underwent apoptosis (IC50) is
6.4 μmol/L (n = 5 patient samples).
CLL cells in lymphoid organs are in
contact with their microenvironment, and
cells of the microenvironment can protect
CLL cells from spontaneous and druginduced apoptosis (31). It is therefore critical to evaluate new compounds in the
context of the cellular microenvironment.
Thus, we examined whether NXT629
could kill CLL cells when cocultured with
macrophages, which can protect CLL
cells from spontaneous apoptosis in vitro
(32). As expected, macrophages protected
CLL cells from spontaneous apoptosis in
vitro (Figure 2B), and addition of NXT629
to these cocultures caused a significant
reduction in CLL cell viability. After 6 d,
the majority of CLL cells underwent apoptosis in the presence of 10 μmol/L
NXT629 (Figure 2B). Because a frontline
therapy for CLL is fludarabine (2), we
compared NXT629 and fludarabine for
their potential to induce apoptosis of CLL
cells in the presence of accessory cells.
Under the same coculture conditions,
CLL cells were completely protected
from fludarabine-induced apoptosis (Figure 2C), at doses that were cytotoxic to
CLL cells cultured in the absence of
macrophages (Figure 2D), whereas
NXT629 induced apoptosis of CLL cells
under both conditions (Figures 2A, B).
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Preadipocytes (OP9 cells [26]) were evaluated for their ability to protect CLL cells
from spontaneous apoptosis, since they
play a supportive role in other cancers
and could be a potential source of lipids
in vivo (33,34). Preadipocytes (OP9 cells)
also increased viability of CLL cells, and
this effect was completely blocked by
using 10 μmol/L NXT629 (Figure 2E).
PPARα Antagonist Inhibits CLL
Proliferation
While the majority of CLL cells present
in blood are in a resting/nondividing
state, up to 1% of the leukemia cells are
“born” each day (35) in lymphoid organs
(36). Although killing the nondividing
cells, which represent the bulk of the
tumor is important, it is beneficial to
have a therapy that will kill the dividing
cells or at least stop proliferation in areas
such as the lymph node and spleen. To
mimic the proliferative compartment of
CLL, we examined the activity of PPARα
inhibition on CLL cells that were induced
to proliferate in vitro. To induce CLL cell
proliferation, the CLL cells were cocultured with allogeneic T cells that were
previously activated with CD3/CD28 microbeads and subsequently treated with
mitomycin C to stop their division (see
Materials and Methods). To demonstrate
CLL B-cell division, CLL cells were labeled with CFSE before coculture with
T cells, and CLL proliferation was analyzed by flow cytometry. Dilution of the
CFSE stain indicates cell division. Two
different T:CLL ratios were evaluated.
A ratio of 1:2 caused more proliferation
and hence was used in all subsequent experiments. At d 5–7, robust CLL proliferation was observed with approximately
three-fold expansion (Figure 3A). To
allow for comparison between CLL samples, it is preferable to use T cells from
the same donor. Thus, T cells were
frozen after the mitomycin C treatment
and compared with fresh T cells for their
ability to induce CLL cell proliferation.
Because frozen and fresh T cells induced
comparable levels of CLL proliferation
(data not shown), frozen T cells were
used in this study. This assay was devel-

Figure 1. Target engagement in CLL cells. (A) Purified CLL cells were incubated with increasing doses of antagonist or vehicle control for 2 h. Subsequently, the synthetic PPARα
agonist GW590735 (purchased from GlaxoSmithKline) was added at 1 μmol/L for 48 h.
Cells were harvested for RNA isolation. PDK4 (a PPARα target gene) expression was measured by real-time PCR. Data are mean ± standard error of the mean (SEM) from six independent experiments using six different CLL donors. Significant difference: *p < 0.05, unpaired Student t test. (B) Purified CLL cells were preincubated with vehicle control (veh),
NXT629 or the control compound NXT962, both at 30 μmol/L for 2 h. Subsequently,
GW590735 was added at 1 μmol/L for 48 h. Cells were analyzed as above. One representative result of two independent experiments using two different CLL donors is shown. Significant difference: *p < 0.05, **p < 0.005, unpaired Student t test. n.s., Nonsignificant. (C, D)
Purified CLL cells were incubated in serum- and glucose-free RPMI with NXT629 for 2 h.
Subsequently, the natural agonist OEA was added at 10 μmol/L for an additional 4 h. Cells
were analyzed for PDK4 (C) or CPT1A (D) as above. Data are the mean ± standard deviation (SD) from independent experiments using four different CLL donors. Significant difference: *p < 0.05, unpaired Student t test.

oped for a 96-well plate using frozen
T cells and is therefore amenable to
high-throughput screening of compounds. It also allows for a better comparison between compounds and between assay runs, since the same batch
of frozen CLL and T cells are used. Furthermore, this allows for a comparison of
different CLL samples using the same
compounds and using the same T cells.
Figure 3B depicts the absolute number of
CLL cells demonstrating an approximately five-fold expansion of CLL cells
in this culture system and a dosedependent inhibition of CLL proliferation with NXT629 (Figure 3A). CLL blast
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formation was not affected by NXT629
(Supplementary Figure 2). The control
compound NXT962 did not inhibit CLL
proliferation (Figure 3B). When testing
the effect of PPARα inhibition on dividing CLL cells, NXT629 reduced the number of leukemia cells undergoing cell division with an IC50 of 9.6 μmol/L (n = 10
different CLL samples) (Figure 3C). Cell
cycle analysis revealed that NXT629 significantly decreases the fraction of cells
in the G2/M phase, but does not alter
the fraction of cells in the G0/1 phase
(Figure 3D). This result suggests that
cells as they are trying to enter division
are not undergoing apoptosis, but instead
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Figure 2. PPARα antagonist is cytotoxic to CLL cells, even in the presence of the microenvironment. (A) CLL cells were cultured in the presence of the PPARα antagonist NXT629 or
DMSO control, added once at the beginning of the culture. CLL cells were harvested
after 4 d and stained with DiOC6/PI and analyzed by flow cytometry. The percentage of
viable cells as determined by gating on DiOC6 bright and PI-negative cells is shown. Data
are mean ± SD for five different experiments with five different CLL donors. The IC50 was
calculated using GraphPad Prism software. (B) CLL cells were cultured alone or in the
presence of mitomycin C–treated J774 macrophages. NXT629 (10 μmol/L) or DMSO was
added once at the beginning of the coculture. Cell viability was measured at d 6 as
above. Data are mean ± SD from two independent experiments using two different CLL
donors. Significant difference: ***p < 0.0005, unpaired Student t test. CLL cells were cultured in the presence (C) or absence (D) of mitomycin C–treated J774 macrophages.
DMSO or fludarabine was added once at the beginning of the coculture. Cell viability
was measured at d 6 as above. Data are mean ± SEM from two independent experiments using two different CLL donors. Significant difference: ***p < 0.0005, unpaired Student t test. n.s., Nonsignificant. (E) CLL cells were culture alone or in the presence of
preadipocytes (OP9) cells. NXT629 (10 μmol/L) or DMSO was added once at the beginning of the coculture. Cell viability was assessed at d 6 as above. Data are mean ± SEM
from two independent experiments using two different CLL donors. Significant difference:
**p < 0.005, unpaired Student t test.

are stalled in G0/1 and prevented from
undergoing cell division.
NXT629 Reduces CLL Tumor Burden in
Two Adoptive Transfer Mouse Models
To model the CLL microenvironment
in vivo, the effect of NXT629 on CLL cells
in lymphoid tissue was evaluated using
a xenograft model described by Herman
et al. (37). CFSE-labeled CLL PBMCs
were injected intravenously and busulfan
was given intraperitoneally (IP) on d 1.
Groups of mice received daily dosing of

saline, NXT629 at 30 mg/kg IP, or fludarabine at 50 mg/kg IP. Studies in rat
showed that the oral bioavailability of
NXT629 is only 10.7%; therefore, intraperitoneal dosing was performed in
our mouse studies. Prior experiments
showed that administration of 10 mg/kg
(IP) NXT629 (called compound 33 by
Bravo et al. [24]) as a saline solution in
mouse yielded good drug coverage
across 24 h (that is, Ctrough = 0.05 μmol/L)
with a calculated plasma area under the
curve of 2.4 μmol/L * h. This amount

should be adequate for target engagement, since the IC50 value in the luciferase
assay is 78 nmol/L. Furthermore, the
maximum plasma concentration was
0.38 μmol/L at 1 h postdose (24). Mice
were killed 4 wks after engraftment, and
the splenocytes were stained with hCD19
and analyzed by flow cytometry. The engrafted population represented 3% of
total splenocytes. The NXT629 treated
mice showed a significant reduction in
disease burden (Figure 4A). Mice were
dosed for 1 month daily, during which
time the mice were observed and body
weights were recorded. The mice treated
with NXT629 showed normal behavior
and insignificant reduction in body
weight (Figure 4A), indicating that there
was no systemic toxicity. On the other
hand, fludarabine-treated mice showed a
dramatic reduction in body weight. In
this mouse model, the CLL cells homed
to the spleen, but did not divide, since
we did not observe CFSE dilution. Thus,
this model provided an in in vivo microenvironment for resting CLL cells.
Because a fraction of CLL cells proliferate in vivo (35), it is critical to evaluate
new treatment modalities on the proliferative compartment. It has been shown
that autologous T cells promote CLL cell
survival and proliferation in NSG mice
(38). To model the proliferative CLL compartment in vivo, a modified protocol of
the xenograft model described by Bagnara et al. (38) was applied. In brief, first,
in vitro activated CLL T cells were adoptively transferred into NSG mice. Subsequently, autologous CLL B cells were
given to those mice in which T-cell engraftment was documented by the presence of CD3+ cells in the blood. This approach is a model of CLL B-cell growth in
vivo, since the transferred leukemic cells
proliferate extensively, often exceeding
six to seven divisions on the basis of
CFSE dilution analyses during the course
of the study. However, the approach is
not a model of CLL disease, since the
transferred clone survives for 4–12 wks;
this time interval varies on the basis of
the CLL sample analyzed. Nevertheless,
during this window, the effects of various

MOL MED 21:410-419, 2015 | MESSMER ET AL. | 415

P PA R α I S V I T A L F O R C L L V I A B I L I T Y

Figure 3. PPARα antagonist inhibits CLL proliferation. (A) To demonstrate CLL proliferation under the described culture conditions, CLL cells
were CFSE-labeled and cocultured with activated allogeneic T cells as described in Materials and Methods. Five days after coculture, CLL
cells were stained with CD19-APC and proliferation was assessed by flow cytometry. The histograms to the right show CFSE profile gated on
CD19+ cells. (B) CLL cells were incubated with either PPARα antagonist NXT629 or the negative control compound NXT962 for 2 h. Subsequently, T cells were added and CLL proliferation was assessed after 5 d. The number of viable cells determined by gating on DiOC6 bright
and PI negative cells with the use of Accuri software is depicted. Data are mean ± SD from three independent experiments using CLL cells
from the same donor. Significant difference: *p < 0.05, **p < 0.005, unpaired Student t test. (C) CLL cells were incubated with either PPARα
antagonist NXT629 or vehicle control for 2 h. Subsequently, T cells were added, and CLL proliferation was assessed after 8 d. The number of
viable cells (DiOC6 bright and PI negative) was quantified by flow cytometry and normalized to the vehicle control, set as 100%. Data are
mean ± SEM from 10 different CLL patient samples. (D) CLL cells were incubated as in (C) and, after 8 d, cell cycle analysis was performed
using PI staining as described in Materials and Methods. Percentage of cells in G2/M and G0/1 phase was normalized to vehicle control.
Data are mean ± SEM from four different CLL donors. Significant difference: *p < 0.05, **p < 0.005, unpaired Student t test.

therapies on CLL growth can be effectively studied. Proliferating CLL B cells
are found most often in the spleen and to
a lesser extent in the bone marrow.
Lymph node infiltration is rarely seen
during the time frame of these studies.
Mice treated in this manner were dosed
daily with 30 mg/kg NXT629 IP, and 2
wks after B-cell administration, recipients
were killed and splenocytes were stained
with mCD45/hCD45/hCD19/hCD5. As
seen in the other CLL model, a marked re-

duction in both the percentage and the
absolute number of hCD19+/hCD5+ CLL
cells was observed in NXT629-treated animals (Figure 4B). These results suggest
that NXT629 delays disease progression
of CLL in vivo.
DISCUSSION
Despite major advances in the field,
there is no curative therapy for CLL to
date (2). All patients inevitably relapse
and retreatment is often limited by re-
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sistance to chemotherapy. Thus, new
therapies are needed. Current treatment
approaches aim at achieving minimal
residual disease, which is associated
with superior long-term outcome (3). A
major focus in the field has been on inhibition of kinases, and little attention
has been given to metabolic pathways.
Recent reports have highlighted the role
of PPARα and FAO in cancer
(14,19,39–41). PPARα KO mice completely suppress metastasis and growth
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Figure 4. CLL mouse model. (A) CLL PBMCs from two patients were labeled with CFSE
and randomized among the groups. The 108 CFSE-labeled cells were injected intravenously into NSG mice (lacking T, B and NK cells). Groups of five mice received daily
dosing of saline: NXT629 at 30 mg/kg IP or fludarabine at 50 mg/kg IP. Mice were killed
4 wks after engraftments, and the splenocytes were stained with hCD19 and analyzed
by flow cytometry. Data are hCD19+/CFSE+ cells normalized to vehicle control. (B) Proliferative model. Groups of mice received daily dosing of saline, NXT629 at 30 mg/kg IP.
Mice were killed 2 wks after engraftments of CLL cells. CLL cells in spleen of NSG mice
were quantified by gating on human CD45+ cells, and a second gate was applied to
determine CD19+/CD5+ CLL cells. Representative flow cytometry plots are depicted to
the left. The absolute number of CLL cells is significantly decreased in NXT629-treated
animals. Data are mean ± SEM. Significant difference: *p < 0.05, unpaired Student t test.
n.s., Nonsignificant.

of primary tumor in Lewis lung carcinoma and melanoma models >100 d
after tumor implantation (42). PPARα is
overexpressed in CLL cells and helps to
protect them from harsh microenvironmental conditions. MK886, a small molecule that is reported to have PPARα
antagonist properties, exhibits anti-CLL
activity in vitro and in vivo (23,30).
Taken together, these observations made
us consider that PPARα may be an important therapeutic target for CLL and
other cancers that use FAO as a metabolic strategy. We have also performed
in-house experiments showing that, unlike NXT629, MK886 is not selective,

since it inhibits the following nuclear
hormone receptors: ERβ (7.5 μmol/L),
TR (11 μmol/L) and GR (10 μmol/L) at
IC50 levels that are lower than or similar
to PPARδ (17 μmol/L), PPARγ
(14 μmol/L) and PPARα (18 μmol/L).
We evaluated MK886 in the luciferase
reporter assay and found that its IC50
for inhibition of PPARα-driven luciferase expression overlapped with the
IC50 for cellular cytotoxicity in the CHO
cells. The strong overlap in toxicity prevents a clear interpretation regarding
whether this molecule does indeed
inhibit PPARα, leading to a decrease in
luciferase signal or that the cytotoxic

effect leads to a decrease in luciferase
signal. NXT629 does not suffer from the
same problem, since it is not cytotoxic
in CHO cells and is highly selective for
PPARα (100-fold or more selective)
(Table 1). To date, there are no highly selective PPARα antagonists that are
available for clinical studies. Taken together, these results strongly suggest
that MK886 is not a good molecule to
study PPARα inhibition, and therefore
our study is the first one to show the effect of PPARα inhibition on CLL cells.
The small molecule PPARα antagonist
NXT629 induced apoptosis in resting
CLL cells and inhibited proliferation of
CLL cells in vitro (Figures 2, 3), but was
less cytotoxic to B cells isolated from
healthy volunteers (Supplementary Figure S1). Because accessory cells can rescue CLL cells from spontaneous and
drug-induced apoptosis (43–45), as well
as protect CLL cells from fludarabineinduced apoptosis in vitro (31), it is essential to evaluate potential therapeutics
in CLL accessory cell cocultures. Importantly, NXT629 induced apoptosis of CLL
cells in the presence of the microenvironment, whereas fludarabine was completely inactive (Figure 2C).
The doses needed to see an effect in
CLL experiments are significantly higher
than the IC50 value in the luciferase reporter assay. We can only speculate as to
why this is the case. The luciferase reporter assay also requires less agonist to
induce gene expression and generally appears more sensitive to both PPARα induction and inhibition. This method is an
artificial system with CHO cells overexpressing a reporter construct. It is not
known which and how many molecules
of corepressor and coactivator are present
in CHO cells in comparison to CLL cells.
All of this could play are role. However,
the dose that is needed to engage the target in CLL cells in vitro is also the dose
that leads to cell death, indicating that the
observed effect on CLL cells in on target.
Furthermore, NXT629 was also found
to lower CLL tumor burden in two different CLL mouse models in vivo (Figure 4).
One CLL mouse model was adopted
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from Herman et al. (37). In contrasts to
Herman et al., who showed proliferation
of CLL cells 3–4 wks postxenograft in the
spleen, we did not observe proliferation
of CLL cells in the spleen. These differences could relate to technical differences
or differences in the patient samples
used in our studies. Therefore, our in
vivo experiment tested the effect of
PPARα inhibition on resting CLL cells,
and the decrease in tumor burden is
most likely due to cytotoxic effects on the
tumor, which is in concordance with the
in vitro results. The second tumor model
(38), also an adoptive transfer model of
CLL, was initially described by Bagnara
et al. In this model, CLL cells proliferate
because of the presence of activated autologous T cells. In concordance with the
in vitro proliferating CLL cultures,
NXT629 lowered tumor burden of proliferating CLL cells in vivo (Figure 4B). In
this mouse model, the majority of CLL
cells reside in the spleen; therefore, the
splenocytes were analyzed, and both the
percentage as well as the absolute number of CLL B cells were reduced in
NXT629-treated animals. In addition to
the spleen, bone marrow was also analyzed. Although significant engraftment
of CLL cells in bone marrow only occurred in two to three mice per group,
the same trend was observed as in the
spleen. NXT629-treated mice contained a
lower number of CD19+/CD5+ human
B cells in the bone marrow (data not
shown). Interestingly, trough levels as
low as 50 nmol/L NXT629 measured in
plasma were sufficient to cause a significant reduction in tumor burden, whereas
in vitro, micromolar levels are needed.
One explanation for the discrepancy between the active dose in vitro and in vivo
could be that CLL cells in their in vivo
microenvironment are more dependent
on β-oxidation compared with in vitro
culture conditions and thus are more
sensitive to its inhibition. On the other
hand, cell culture media contain high
levels of glucose, which could provide
one possible alternative energy source to
fatty acids in vitro and therefore lower
the dependency on FAO and reduce the

sensitivity to PPARα inhibition. However, removal of glucose in vitro did not
increase sensitivity of CLL cells to
PPARα inhibition (data not shown), ruling out the possibility of a metabolic
switch to glucose in vitro. Another alternative energy source could be glutamine,
whose role remains to be investigated. A
further consideration was that CLL cells
might encounter hypoxic conditions in
vivo and thus be more sensitive to inhibition of PPARα. However, culture of CLL
cells in vitro at low oxygen failed to increase sensitivity to PPARα inhibition
(data not shown).
Alternatively, NXT629 could affect certain cells of the microenvironment in
vivo, which after exposure to NXT629
could withdraw support factors. As a
consequence of this, CLL cells could undergo apoptosis. Indeed, it is likely a
combination of factors where in vivo the
antagonist acts on both the CLL cells and
the microenvironment. All these questions remain to be investigated.
CONCLUSION
Overall, our preclinical data demonstrate sensitivity of CLL cells to PPARα
inhibition and show PPARα antagonist–
mediated cytotoxicity in vitro and in vivo,
suggesting that antagonism of PPARα
might be a potent and safe new therapeutic target for CLL. Spaner et al. (23)
showed that PPARα expression was
highly associated with advanced-stage
disease. Thus, PPAR expression could be
used to select the patient population that
would benefit from treatment. Blocking a
fundamental fuel source might not allow
for escape mutants as, for example, inhibition of kinases does. However, combination therapies will most likely be more
efficacious.
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